Compare Medpace Holdings Inc (MEDP) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Oklo Inc — how do they compare? Medpace Holdings Inc trades at $614.17 (market cap $16.82B), while Oklo Inc trades at $34.44 (market cap $6.43B). The key difference: Medpace Holdings Inc is far larger — about 2.6× Oklo Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Oklo Inc for 32 Days on average.
| MEDP | OKLO | |
|---|---|---|
Market Cap | $16.82B | $6.43B |
Volume | 223,093 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $630.19 | $174.14 |
52-Week Low | $393.42 | $34.57 |
Typical Hold Time | 14 Days | 32 Days |
Enterprise Value | $16.44B | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
OKLO trades at $34.65, down 5.91% today, with a bearish technical signal from moving averages. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Analyst consensus remains strongly bullish with a $78.63 price target, but recent news highlights competitive pressures and dilution concerns from stock sales.
The outlook hinges on OKLO's ability to commercialize its nuclear reactor pipeline. High institutional buy ratings suggest long-term potential, but execution risks, cash burn, and intense competition in the SMR space pose significant challenges. The stock offers speculative growth exposure amid substantial operational and financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
